A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

NCT03505554 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Anaplastic Large Cell Lymphoma, ALK-Positive

Interventions

DRUG: Lorlatinib

Sponsor

University of Milano Bicocca

Collaborators

[object Object]